The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: A pilot study

Rhinology

Volumn 47, Issue 1, 2009, Pages 85-88

  De Gussem, E M ^a   Snijder, R J ^a   Disch, F J ^a   Zanen, P ^a   Westermann, C J J ^a   Mager, J J ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Epistaxis; HHT; N acetylcysteine; Quality of life; Rendu Osler Weber

Indexed keywords

ACETYLCYSTEINE; SCAVENGER;

ARTICLE; CLINICAL TRIAL; EPISTAXIS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME;

ACETYLCYSTEINE; EPISTAXIS; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME;

EID: 62649172211     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Guttmacher AE, Marchuk DA, White RI, Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-924.
2. Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003; 116: 324-328.
3. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-76.
4. McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, et al. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet 1994; 6: 197-204.
5. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
6. Lesca G, Burnichon N, Raux G, et al. Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat 2006; 27: 598.
7. Pasculli G, Resta F, Guastamacchia E, et al. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 2004; 13: 1715-1723.
8. OS AA, Friedman CM, White RI, Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101: 977-890.
9. Saunders WH. Septal dermoplasty: a new operative procedure for control of nosebleeds in patients with hereditary haemorrhagic telangiectasia. J Laryngol Otol 1963; 77: 69-76.
10. Siegel MB, Keane WM, Atkins JF, Jr., Rosen MR. Control of epistaxis in patients with hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1991; 105: 675-679.
11. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997; 111: 30-33.
12. Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96: 684-692.
13. Felix K, Pairet M, Zimmermann R. The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study. Life Sci 1996; 59: 1141-1147.
14. Benrahmoune M, Therond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic Biol Med 2000; 29: 775-782.
15. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990; 30: 603-631.